CD40LG and COVID-19: The described case illustrates all of the risks associated with this malignancy in the context of COVID-19—prolonged in-hospital stay, the fatality of the disease, and as the antibody level investigations revealed—impaired humoral immune response as neither SARS-CoV-2-specific IgM, IgA nor IgG class antibodies were detected.